Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial-Reference-Cited by-同舟云学术

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Published:2008-03 Issue:3 Volume:63 Page:395-400
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Bar-Or Amit,Calabresi Peter A. J.,Arnold Douglas,Markowitz Clyde,Shafer Stuart,Kasper Lloyd H.,Waubant Emmanuelle,Gazda Suzanne,Fox Robert J.,Panzara Michael,Sarkar Neena,Agarwal Sunil,Smith Craig H.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference27 articles.

1. Immunology of multiple sclerosis;Sospedra;Annu Rev Immunol,2005

2. Autoimmune inflammation from the Th17 perspective;Furuzawa-Carballeda;Autoimmun Rev,2007

3. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;IFNb Multiple Sclerosis Study Group;Neurology,1993

4. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial;Johnson;Neurology,1995

5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann Neurol,1996

Cited by 453 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease;Current Neurology and Neuroscience Reports;2024-09-11

2. Rituximab in secondary progressive multiple sclerosis: a meta‐analysis;Annals of Clinical and Translational Neurology;2024-08-26

3. Dynamic alterations of dural and bone marrow B cells in an animal model of progressive multiple sclerosis;2024-08-26

4. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

5. Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab;Meditsinskiy sovet = Medical Council;2024-08-15